


**Product Name** : Ravoxertinib  
**Cat. No.** : PC-22330  
**CAS No.** : 1453848-26-4  
**Molecular Formula** : C<sub>21</sub>H<sub>18</sub>ClFN<sub>6</sub>O<sub>2</sub>  
**Molecular Weight** : 440.86  
**Target** : ERK  
**Solubility** : 10 mM in DMSO



## Biological Activity

Ravoxertinib (GDC-0994) is potent, selective and orally active ERK kinase inhibitor with IC<sub>50</sub> of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

Ravoxertinib (GDC-0994) displays at least 50-fold selectivity against the Invitrogen Selectscreen panel containing 279 kinases.

Ravoxertinib (GDC-0994) potently inhibits ERK dependent p90RSK serine 380 phosphorylation in PMA-stimulated HepG2 cells with IC<sub>50</sub> of 12 nM.

Ravoxertinib (GDC-0994) decreases the viability of lung adenocarcinoma cell lines (A549, HCC827, HCC4006).

Ravoxertinib (GDC-0994) (15, 30, or 100 mg/kg, PO, QD) inhibits tumor growth in the HCT116 mouse xenograft model.

## References

Blake JF, et al. J Med Chem. 2016 Jun 23;59(12):5650-60.

Varga A, Soria JC, et al. Clin Cancer Res. 2020 Mar 15;26(6):1229-1236.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com